Helicobacter Pylori Infections – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Helicobacter pylori (H. pylori) is a Gram-negative, helix-shaped, microaerophilic, flagellated bacterium capable of converting its shape from spiral to coccoid, which is believed to be to be involved in the enhancement of bacterial survival in the host gastric microenvironment.

·       H pylori cause acute gastritis characterized by neutrophil infiltration into the foveolar and surface epithelium and degenerative epithelial changes. H pylori cause a persistent infection in the majority of infected individuals.

·       Long-term infection by H pylori results in chronic gastritis, a condition manifest as multiple pathologic entities. Due to H pylori infection, chronic gastritis may be separated into distinct, clinically relevant phenotypes. Nonatrophic pangastritis occurs in most H pylori-infected individuals with no predisposition to peptic ulcer disease or gastric atrophy.

·       Bacterial and host factors seem to influence the type of gastroduodenal disease that is generated. As many as 16% of H pylori-infected individuals in the United States develop duodenal ulcers in addition to chronic active gastritis. An inverse relationship or paradox exists between the incidence of duodenal ulcer disease and gastric adenocarcinoma.

 

The competitive landscape of Helicobacter Pylori Infections includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Helicobacter Pylori Infections across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Helicobacter Pylori Infections Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Helicobacter Pylori Infections – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Vonoprazan      Phathom Pharmaceuticals, Inc.  Phase 3

2          Dietary Supplement: Lacidofil     Lallemand Health Solutions            Phase 3

3          H.pylori vaccines           Novartis            Phase 1

4          Tegoprazan      HK inno.N Corporation   Phase 3

5          BreathID® Hp System   Exalenz Bioscience LTD.           Phase 3

6          Vonoprazan      Takeda Phase 3

7          RHB-105           RedHill Biopharma Limited         Phase 3

8          Omeprazole, amoxicillin, clarithromycin  Forest Laboratories            Phase 3